CHA2DS2-VASc评分对急性心肌梗死患者行冠状动脉介入治疗无复流现象预测

Prediction of no reflow phenomenon in patients with acute myocardial infarction undergoing coronary intervention by CHA2DS2-VASc score

目的本研究旨在验证CHA2DS2-VASc评分对直接经皮冠状动脉介入治疗(PCI)的ST段抬高型心肌梗死(STEMI)患者无复流现象的临床预测价值。方法将我院收治接受原发性PCI治疗的300例STEMI患者分为两组:将27例无复流患者作为第一组,将其余273例患者作为对照组。计算每例患者CHA2DS2-VASc风险评分。结果CHA2DS2-VASc评分与无复流相关性的多变量分析差异有统计学意义(P<0.05)。CHA2DS2-VASc评分中各个成分对无复流预测能力差异有统计学意义(P<0.05)。结论在接受PCI治疗的STEMI患者中,较高的CA2DS2-VASc评分与无复流现象风险和住院病死率相关。

Objective To verify the clinical predictive value of CHA2DS2-VASc score in the absence of reflow in ST-segment elevation myocardial infarction(STEMI)patients after direct percutaneous coronary intervention(PCI).Methods 300 STEMI patients admitted to our hospital for primary PCI were divided into two groups:27 patients without reflow as the first group,and the remaining 273 patients as the control group.CHA2DS2-VASc risk score was calculated for each patient.Results There was statistically significant difference in multivariate analysis between CHA2DS2-VASc score and non-reflow correlation(P<0.05).The components of CHA2DS2-VASc score showed significant differences in the prediction ability of non-reflow(P<0.05).Conclusion In STEMI patients treated with primary PCI,higher CHA2DS2-VASc score was associated with the risk of no reflow and in-hospital mortality.